Our results suggest that the lncRNA TUG1 might be a useful prognostic biomarker in ICC patients and also a novel therapeutic target to prevent or counteract metabolic reprogramming in ICC. Here, TUG1 is linked to intrahepatic cholangiocarcinoma.